De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients
- 174 Downloads
The reduction in the burden related to treatment is becoming more and more important in modern oncology. Radiation therapy is a mainstay option in the postoperative setting for early breast cancer patients after breast-conserving surgery. Nowadays, different options are available to de-escalate radiotherapy in this scenario such as the use of hypofractionated whole-breast radiation, the selective delivery of the boost dose to the lumpectomy cavity, the introduction of accelerated partial breast irradiation and the omission of treatment in appropriately selected patients with low-risk features. We herein provide a review article on this topic.
KeywordsDe-escalation Whole-breast radiation Hypofractionation Accelerated partial breast irradiation Boost Radiotherapy omission Breast cancer
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
- 4.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, et al. Effects of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.CrossRefGoogle Scholar
- 8.Cante D, Rosa La Porta M, Casanova-Borca V, Sciacero P, Girelli G, Pasquino M, et al. Accelerated hypofractionated adjuvant radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients. Breast J. 2011;17:586–93.CrossRefPubMedGoogle Scholar
- 10.The START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet Oncol. 2008;9:331–41.CrossRefPubMedCentralGoogle Scholar
- 11.Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barret J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomized trials. Lancet Oncol. 2013;14:1086–94.CrossRefPubMedGoogle Scholar
- 15.Hopwood P, Haviland JS, Sumo G, Mills J, Bliss JM, Yarnold JR, START Trial Management Group. Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncol. 2010;11:231–40.CrossRefPubMedGoogle Scholar
- 17.Jagsi R, Griffith KA, Boike TP, Walker E, Nurushev T, Grills IS, et al. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule: comparative analysis of physician assessed and patient-reported outcomes in a large multicenter cohort. JAMA Oncol. 2015;1:918–30.CrossRefPubMedGoogle Scholar
- 19.Rovea P, Fozza A, Franco P, De Colle C, Cannizzaro A, Di Dio A, et al. Once-weekly hypofractionated whole-breast radiotherapy after breast-conserving surgery in older patients: a potential alternative treatment schedule to daily 3-week hypofractionation. Clin Breast Cancer. 2015;15:270–6.CrossRefPubMedGoogle Scholar
- 20.Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol. 2016;120:114–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Coles C, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicenter, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390:1048–60.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S, Saieva C, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase-3 randomised controlled trial. Eur J Cancer. 2015;51:451–63.CrossRefPubMedGoogle Scholar
- 25.Meattini I, Saieva C, Miccinesi G, Desideri I, Francolini G, Scotti V, et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. Eur J Cancer. 2017;51:17–26.CrossRefGoogle Scholar
- 28.NSABP B-39/RTOG 0413. A randomized Phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with Stage 0, I, or II breast cancer. https://www.rtog.org. Accessed 8 Mar 2018.
- 29.Olivotto I, Whelan T, Parpia S, Kim DH, Berrang T, Truong PT, et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol. 2013;31:4038–45.CrossRefPubMedGoogle Scholar
- 33.Lovey K, Fodor J, Major T, Szabo’ E, Orosz Z, Sulyok Z, et al. Fat necrosis after partial-breast irradiation with brachytherapy or electron irradiation versus standard whole-breast radiotherapy—4-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:724–31.CrossRefPubMedGoogle Scholar
- 34.Ott OJ, Strnad V, Hildebrandt Kauer-Dorner D, Knauerhase H, Major T, et al. GEC-ESTRO multicenter phase 3-trial: accelerated partial breast irradiation with interstitial multicatheter brachytherapy versus external bream whole breast irradiation: early toxicity and patient compliance. Radiother Oncol. 2016;120:119–23.CrossRefPubMedGoogle Scholar
- 35.Strnad V, Ott OJ, Hildebrandt GH, Kauer-Dorner D, Knauerhase H, Major T, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: a randomised phase 3, non-inferiority trial. Lancet. 2016;387:229–38.CrossRefPubMedGoogle Scholar
- 36.Polgar C, Ott OJ, Hildebrandt GH, Kauer-Dorner D, Knauerhase H, Major T, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:259–68.CrossRefPubMedGoogle Scholar
- 39.Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376:91–102.CrossRefPubMedGoogle Scholar
- 40.Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383:603–13.CrossRefPubMedGoogle Scholar
- 42.Bartelink H, Horiot J-C, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2001;345:1378–87.CrossRefPubMedGoogle Scholar
- 43.Bartelink H, Horiot J-C, Poortmans P, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of higher radiation dose on local control, survival in breast-conserving therapy of early breast cancer: 10 years results of the randomized boost versus no boost EORTC trial 22881-10882. J Clin Oncol. 2007;25:3259–65.CrossRefPubMedGoogle Scholar
- 44.Bartelink H, Maingon P, Poortmans P, Weltesn C, Fourquet A, Jager J, et al. Whole breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow up of a randomised phase 3 trial. Lancet Oncol. 2015;16:47–56.CrossRefPubMedGoogle Scholar
- 48.Cante D, Franco P, Sciacero P, Girelli G, Marra AM, Pasquino M, et al. Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer. Med Oncol. 2013;30:518.CrossRefPubMedGoogle Scholar
- 50.Cante D, Petrucci E, Sciacero P, Piva C, Ferrario S, Bagnera S, et al. Ten-year results of accelerated hypofractionated adjuvant whole-breast radiation with concomitant boost to the lumpectomy cavity after conserving surgery for early breast cancer. Med Oncol. 2017;34:152.CrossRefPubMedGoogle Scholar
- 51.Franco P, Zeverino M, Migliaccio F, Cante D, Sciecero P, Casanova Borca V, et al. Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing static port of tomotherapy (TomoDirect): a prospective phase II trial. J Cancer Res Clin Oncol. 2014;140:167–77.CrossRefPubMedGoogle Scholar
- 53.RTOG 1005. A Phase III trial of accelerated whole breast irradiation with hypofractionation plus concurrent boost versus standard whole breast irradiation plus sequential boost for early-stage breast cancer. www.rtog.org. Accessed 3 Mar 2018.
- 57.Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20:4141–9.CrossRefPubMedGoogle Scholar
- 61.Tinterri C, Gatzemeier W, Costa A, Gentilini MA, Zanini V, Regolo L, et al. Breast-conservative surgery with and without radiotherapy in patients aged 55–75 years with early-stage breast cancer: a prospective, randomized, multicenter trial analysis after 108 months of median follow-up. Ann Surg Oncol. 2014;21:408–15.CrossRefPubMedGoogle Scholar
- 65.Liu FF, Shi W, Done SJ, Miller N, Pintillie M, Voduc D, et al. Identification of a low-risk luminal A breast cancer cohort that may not benefit from breast radiotherapy. J Clin Oncol. 2015;33:1–6.Google Scholar
- 67.The IDEA (Individualized Decisions for Endocrine therApy) study at ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02400190. Accessed 10 Mar 2018.
- 68.Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28:1677–83.CrossRefPubMedPubMedCentralGoogle Scholar
- 69.The PRECISION (Profiling Early Breast Cancer for Radiotherapy Omission) trial at ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02653755. Accessed 10 Mar 2018.
- 71.Cuzik J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4273–8.CrossRefGoogle Scholar
- 72.A prospective cohort study evaluating risk of local recurrence following breast conserving surgery and endocrine therapy in low risk LUMINAL A Breast cancer (LUMINA) at ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01791829. Accessed 10 Mar 2018.
- 75.Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28:1700–12.CrossRefPubMedGoogle Scholar